GSK Advair Diskus Clears FDA For COPD; Bone Density Study In Phase IV

GlaxoSmithKline will study Advair Diskus 250/50 for its effects on bone mineral density as one Phase IV commitment following FDA's Nov. 17 supplemental approval for chronic obstructive pulmonary disease associated with bronchitis